Unlike HFrEF, where multiple therapies are routinely initiated during admission, HFpEF management is more heavily centered on volume optimization, blood pressure control, and treatment of comorbidities such as atrial fibrillation, coronary artery disease, chronic kidney disease, and obesity
Some individual providers may have exited the market or experienced supply delays, creating localized perception of discontinuation without representing industry-wide shutdown
There may be risk of cardiac arrhythmias
Sources: Eli Lilly and Company
Ensuring accurate dosage is a vital part of any research protocol
Surgical Approaches to Volume Restoration Surgical interventions often become necessary when volume loss is accompanied by tissue descent and skin laxity that cannot be adequately addressed with injectables or nonsurgical techniques alone, said Grob